BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 26205471)

  • 1. Expression of proteins involved in DNA damage response in familial and sporadic breast cancer patients.
    Partipilo G; Simone G; Scattone A; Scarpi E; Azzariti A; Mangia A
    Int J Cancer; 2016 Jan; 138(1):110-20. PubMed ID: 26205471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biological and clinical significance of PARP1 protein expression in breast cancer.
    Green AR; Caracappa D; Benhasouna AA; Alshareeda A; Nolan CC; Macmillan RD; Madhusudan S; Ellis IO; Rakha EA
    Breast Cancer Res Treat; 2015 Jan; 149(2):353-62. PubMed ID: 25528020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nuclear PARP1 expression and its prognostic significance in breast cancer patients.
    Mazzotta A; Partipilo G; De Summa S; Giotta F; Simone G; Mangia A
    Tumour Biol; 2016 May; 37(5):6143-53. PubMed ID: 26614429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA damage response markers are differentially expressed in BRCA-mutated breast cancers.
    Aleskandarany M; Caracappa D; Nolan CC; Macmillan RD; Ellis IO; Rakha EA; Green AR
    Breast Cancer Res Treat; 2015 Feb; 150(1):81-90. PubMed ID: 25690937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NHERF1 together with PARP1 and BRCA1 expression as a new potential biomarker to stratify breast cancer patients.
    Mangia A; Scarpi E; Partipilo G; Schirosi L; Opinto G; Giotta F; Simone G
    Oncotarget; 2017 Sep; 8(39):65730-65742. PubMed ID: 29029467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRCA1 protein expression and its correlation with ER/PR status in sporadic and familial breast cancer in Eastern Indian patients--a hospital based study.
    Ashraf M; Jha JK; Mukherjee N; Panda CK; Nayak S; Jadhav TS; Dikshit N; Nath NC; Chakraborty J; Biswas J
    J Indian Med Assoc; 2011 Dec; 109(12):873-8. PubMed ID: 23469566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polymorphisms in poly (ADP-ribose) polymerase-1 (PARP1) promoter and 3' untranslated region and their association with PARP1 expression in breast cancer patients.
    Zhai L; Li S; Li H; Zheng Y; Lang R; Fan Y; Gu F; Guo X; Zhang X; Fu L
    Int J Clin Exp Pathol; 2015; 8(6):7059-71. PubMed ID: 26261599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phenotypic analysis of familial breast cancer: comparison of BRCAx tumors with BRCA1-, BRCA2-carriers and non-familial breast cancer.
    Aloraifi F; Alshehhi M; McDevitt T; Cody N; Meany M; O'Doherty A; Quinn CM; Green AJ; Bracken A; Geraghty JG
    Eur J Surg Oncol; 2015 May; 41(5):641-6. PubMed ID: 25736863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Poly(adenosine diphosphate-ribose) polymerase expression in BRCA-proficient ovarian high-grade serous carcinoma; association with patient survival.
    Gan A; Green AR; Nolan CC; Martin S; Deen S
    Hum Pathol; 2013 Aug; 44(8):1638-47. PubMed ID: 23574784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Higher cytoplasmic and nuclear poly(ADP-ribose) polymerase expression in familial than in sporadic breast cancer.
    Klauke ML; Hoogerbrugge N; Budczies J; Bult P; Prinzler J; Radke C; van Krieken JH; Dietel M; Denkert C; Müller BM
    Virchows Arch; 2012 Oct; 461(4):425-31. PubMed ID: 22968923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Familial breast cancers without mutations in BRCA1 or BRCA2 have low cyclin E and high cyclin D1 in contrast to cancers in BRCA mutation carriers.
    Aaltonen K; Blomqvist C; Amini RM; Eerola H; Aittomäki K; Heikkilä P; Nevanlinna H
    Clin Cancer Res; 2008 Apr; 14(7):1976-83. PubMed ID: 18381935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autoimmune response to PARP and BRCA1/BRCA2 in cancer.
    Zhu Q; Han SX; Zhou CY; Cai MJ; Dai LP; Zhang JY
    Oncotarget; 2015 May; 6(13):11575-84. PubMed ID: 25865228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short telomeres are frequent in hereditary breast tumors and are associated with high tumor grade.
    Martinez-Delgado B; Gallardo M; Tanic M; Yanowsky K; Inglada-Perez L; Barroso A; Rodriguez-Pinilla M; Cañamero M; Blasco MA; Benitez J
    Breast Cancer Res Treat; 2013 Sep; 141(2):231-42. PubMed ID: 24036693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer.
    Nishimukai A; Yagi T; Yanai A; Miyagawa Y; Enomoto Y; Murase K; Imamura M; Takatsuka Y; Sakita I; Hatada T; Miyoshi Y
    Clin Breast Cancer; 2015 Jun; 15(3):204-11. PubMed ID: 25600243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunoprofile from tissue microarrays to stratify familial breast cancer patients.
    Schirosi L; De Summa S; Tommasi S; Paradiso A; Sambiasi D; Popescu O; Simone G; Mangia A
    Oncotarget; 2015 Sep; 6(29):27865-79. PubMed ID: 26312763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PARP1 and phospho-p65 protein expression is increased in human HER2-positive breast cancers.
    Stanley J; Klepczyk L; Keene K; Wei S; Li Y; Forero A; Grizzle W; Wielgos M; Brazelton J; LoBuglio AF; Yang ES
    Breast Cancer Res Treat; 2015 Apr; 150(3):569-79. PubMed ID: 25833211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human epidermal growth factor receptor 2, Na+/H+ exchanger regulatory factor 1, and breast cancer susceptibility gene-1 as new biomarkers for familial breast cancers.
    Mangia A; Malfettone A; Saponaro C; Tommasi S; Simone G; Paradiso A
    Hum Pathol; 2011 Nov; 42(11):1589-95. PubMed ID: 21496870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bcl-2 is a highly significant prognostic marker of hormone-receptor-positive, human epidermal growth factor receptor-2-negative breast cancer.
    Seong MK; Lee JY; Byeon J; Sohn YJ; Seol H; Lee JK; Kim EK; Kim HA; Noh WC
    Breast Cancer Res Treat; 2015 Feb; 150(1):141-8. PubMed ID: 25682076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunohistochemical expression of BRCA1 protein in invasive ductal carcinoma of the breast.
    Burkadze G; Khardzeishvili O; Gudadze M; Tsikhiseli G; Turashvili G
    Georgian Med News; 2010; (184-185):51-60. PubMed ID: 20834076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of the forkhead box transcription factor FOXP1 is associated with oestrogen receptor alpha, oestrogen receptor beta and improved survival in familial breast cancers.
    Rayoo M; Yan M; Takano EA; Bates GJ; Brown PJ; Banham AH; Fox SB
    J Clin Pathol; 2009 Oct; 62(10):896-902. PubMed ID: 19622517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.